Glucose Intravenous Infusion Bp B. Braun Medical

Glucose Intravenous Infusion Bp B. Braun Medical is an intravenous solution containing glucose monohydrate as the active ingredient. It is supplied in a liquid form for parenteral administration. The product is manufactured according to European Union standards and is available by prescription for use in clinical settings to provide a rapid source of carbohydrate energy. It is used when oral intake is insufficient or when correction of hypoglycemia is required.

Glucose Intravenous Infusion Bp B. Braun Medical is employed in several clinical situations where an immediate source of glucose is needed.

- Management of peri‑operative fluid and energy needs. - Treatment of hypoglycemia when oral glucose is not feasible. - Provision of calories in patients receiving total parenteral nutrition. - Support during prolonged fasting or starvation. - Electrolyte‑balanced carrier for drug dilution in some protocols.

Adverse reactions to glucose intravenous solutions are generally related to the infusion itself and the osmolar load.

Common: - Mild hyperglycemia. - Local irritation at the infusion site. - Nausea or vomiting. - Headache. - Transient electrolyte shifts, such as mild hyponatremia.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload causing pulmonary edema. - Hyperosmolar hyperglycemic state (HHS) in susceptible patients. - Allergic or anaphylactic reaction to excipients.

Clinicians should evaluate patient-specific factors before initiating a glucose infusion.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor fluid balance to avoid overload, especially in cardiac or renal impairment. - Use caution in patients with diabetes mellitus or insulin resistance. - Verify compatibility with other intravenous medications before co‑administration. - Consider electrolyte composition, particularly sodium and potassium levels, to prevent imbalances. - Avoid rapid infusion in neonates and infants due to risk of hyperglycemia.

Glucose solutions can interact with other intravenous agents or affect the pharmacodynamics of certain drugs.

Avoid: - Co‑infusion with high‑dose insulin without appropriate monitoring. - Simultaneous administration of drugs that require a low‑glucose environment, such as certain chemotherapeutics.

Use with caution: - Concurrent use of diuretics that may alter fluid status. - Medications that affect serum potassium (e.g., ACE inhibitors, potassium‑sparing diuretics). - Vasopressors, as changes in intravascular volume can modify their effect.